Geo Group Inc (The) REIT vs uniQure N.V. Ordinary Shares — how do they compare? Geo Group Inc (The) REIT trades at $30.81 (market cap $4.24B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Geo Group Inc (The) REIT is far larger — about 2.9× uniQure N.V. Ordinary Shares's market cap, and Geo Group Inc (The) REIT is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Geo Group Inc (The) REIT for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GEO | QURE | |
|---|---|---|
Market Cap | $4.24B | $1.48B |
Volume | 1,580,830 | 2,488,780 |
Sector | Industrials | Health |
52-Week High | $32.77 | $70.59 |
52-Week Low | $13.26 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.79B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
GEO trades at $32.19, up 1.45% today, with a bullish technical signal from moving averages. Recent earnings beats in Q1 and Q2 2026, alongside a net income margin of 10.31% and ROE of 20.11%, highlight strong profitability. The company recently sold its Adelanto facilities for $950 million and increased its share repurchase authorization to $1.25 billion, signaling financial strength and shareholder returns.
The outlook is positive, supported by analyst consensus (66.7% buy ratings) and recent Zacks upgrades to Strong Buy. Key opportunities include earnings momentum and strategic asset sales, while risks involve debt management and potential regulatory scrutiny. The stock's valuation, with a P/E of 15.18, appears reasonable given growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The GEO Group provides correctional, detention, and community reentry services. Its operations include secure facilities, electronic monitoring, and support programs for individuals in the criminal-justice system.
Read more on GEO →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →